FDA Determines Regulatory Review Period for Ziagen Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Ziagen TM, a human drug product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office, as required by law.